Mateon Therapeutics to Present at 29th Annual ROTH
Post# of 301275
SOUTH SAN FRANCISCO, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 29 th Annual ROTH Conference taking place from March 12-15, 2017 in Dana Point, California.
Mateon’s management will present a company overview on Wednesday, March 15, 2017 at 7:30 am pacific time. A live webcast of the presentation will be available on the company’s website at www.mateon.com in “Events & Presentations” under the “Investors & News” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
About Mateon Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACTS Investors: PCG Advisory Group Stephanie Prince, Managing Director sprince@pcgadvisory.com 646-762-4518 Media: JPA Health Communications Nic DiBella nic@jpa.com 617-945-5183
(0)
(0)